<DOC>
	<DOCNO>NCT01107743</DOCNO>
	<brief_summary>In survey , collect safety efficacy information Amlodipine /Atorvastatin ( Caduet® Combination Tablets ) daily medical practice examine . In addition , necessity special Investigation post-marketing clinical study examine , investigate unexpected adverse drug reaction survey period understand status frequency adverse drug reaction daily medical practice .</brief_summary>
	<brief_title>Amlodipine/Atorvastatin ( Caduet® ) Drug Use Investigation ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>All subject investigator prescribes first Amlodipine /Atorvastatin ( Caduet® ) Combination Tablets register consecutively number subject reach target number order extract patient enrol investigation random .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Amlodipine , atorvastatin drug combination</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male Female subject intend treat cardiovascular disease prescribe Amlodipine /Atorvastatin ( Caduet® ) Combination Tablets Physicians Subjects prescribe Amlodipine /Atorvastatin ( Caduet® ) Combination Tablets .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Hypertension</keyword>
	<keyword>Angina pectoris</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>Familial hypercholesterolemia</keyword>
	<keyword>Japanese</keyword>
	<keyword>caduet</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>